Caplight Directory>Companies>Ten63 Therapeutics-preview>Ten63tx


Ten63 Therapeutics

Ten63 Therapeutics

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://ten63tx.com/

Last Round

Strategic

Feb 19, 2026

Total Funding Raised

$67M

Company Overview

Ten63 Therapeutics is a biotechnology company that has developed a proprietary AI drug-discovery platform, BEYOND, to create therapeutics for previously undruggable targets, with an initial focus on oncology.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Medical AI, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Infrastructure

Keywords

AI drug discoveryundruggable targetsgenerative chemistrysmall molecule discoverycomputational drug discoveryin silico drug discoverydrug discovery platformAI biotechtechbiophysics-based modelsoncology drug discoveryquantum mechanics simulationLarge Quantum Chemistry Modeldrug resistance predictionLQCMbiopharma partnershipsMyc oncogene

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ten63 Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ten63 Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
StrategicFeb 19, 2026
StrategicFeb 19, 2026
Series AMay 2, 2023
SeedApr 5, 2019
View all Funding Rounds

Key People

Founding team and executive leadership

Mark Hallen

Co-founder And CTO

Founding Team

Marcel Frenkel

Chief Executive Officer, Founder

Founding Team

Ten63 Therapeutics Investors

Notable investors and investment history

InvestorRounds
Hatteras Venture PartnersStrategic, Series A
Gates FoundationStrategic
Chugai Venture FundStrategic
RYSE Asset ManagementStrategic
Panorama Point PartnersStrategic
K5 GlobalStrategic
Morpheus VenturesSeries A, Strategic, Seed
View all Investors

Ten63 Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ten63 Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ten63 Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range28
Year Founded2019
Last FundingFeb 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.